Bure Equity AB
Moberg Pharma is a Swedish pharmaceutical company that commercializes proprietary, acquired and licensed products in the global market. Initially, the company specializes in the treatment of skin diseases but is now widening its scope. Moberg Pharma markets OTC brands in the U.S. and sells through distributors in more than 40 countries. Moberg Pharma has sales of SEK 157 million.
Directed issue to Bure Equity AB of SEK 36 million to fund acquisition of new marketed products and development projects.
HDR Partners identified potential investors, led negotiations and made arrangement of settlement. HDR also drafted a prospectus to be filed and approved by the Swedish Financial Supervisory Authority.